1104 related items for PubMed ID: 16060910
1. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[Abstract] [Full Text] [Related]
2. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[Abstract] [Full Text] [Related]
3. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[Abstract] [Full Text] [Related]
4. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.
Horm Res; 2004 Mar; 62(5):227-32. PubMed ID: 15477693
[Abstract] [Full Text] [Related]
5. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE, Thornton-Jones VA, Wass JA.
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[Abstract] [Full Text] [Related]
6. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[Abstract] [Full Text] [Related]
7. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G.
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[Abstract] [Full Text] [Related]
8. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA, Wu Z, Silva CM, Barbosa FR, Dias JS, Schrank Y, Strasburger CJ, Gadelha MR.
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[Abstract] [Full Text] [Related]
9. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Carlsen SM, Svartberg J, Schreiner T, Aanderud S, Johannesen O, Skeie S, Lund-Johansen M, Fougner SL, Bollerslev J, POTA study group.
Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
[Abstract] [Full Text] [Related]
10. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F, Magony S, Julesz J.
Orv Hetil; 2002 May 12; 143(19 Suppl):1062-6. PubMed ID: 12063861
[Abstract] [Full Text] [Related]
11. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N, Mészáros J, Czirják S, Mondok A, Varga I, Gláz E.
Orv Hetil; 2002 May 12; 143(19 Suppl):1066-70. PubMed ID: 12063862
[Abstract] [Full Text] [Related]
12. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Jallad RS, Bronstein MD.
Neuroendocrinology; 2009 May 12; 90(1):82-92. PubMed ID: 19439914
[Abstract] [Full Text] [Related]
13. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR.
Taboada GF, Correa LL, de Oliveira Machado E, van Haute FR, Casini AF, Balarini GA, Neto LV, Calixto L, Calixto C, Gadelha MR.
Growth Horm IGF Res; 2007 Feb 12; 17(1):77-81. PubMed ID: 17314058
[Abstract] [Full Text] [Related]
14. Octreotide as primary therapy for acromegaly.
Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
J Clin Endocrinol Metab; 1998 Sep 12; 83(9):3034-40. PubMed ID: 9745397
[Abstract] [Full Text] [Related]
15. [Evaluation of the efficacy of Octreotide LAR in the treatment of acromegaly--a yearly observation].
Bałdys-Waligórska A, Gołkowski F, Krzentowska A, Sokołowski G, Hubalewska-Dydejczyk A.
Przegl Lek; 2009 Sep 12; 66(5):218-21. PubMed ID: 19739577
[Abstract] [Full Text] [Related]
16. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F.
Growth Horm IGF Res; 2005 Jun 12; 15(3):200-6. PubMed ID: 15935982
[Abstract] [Full Text] [Related]
17. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC.
Clin Endocrinol (Oxf); 2009 May 12; 70(5):757-68. PubMed ID: 19178516
[Abstract] [Full Text] [Related]
18. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G.
J Clin Endocrinol Metab; 2006 Apr 12; 91(4):1397-403. PubMed ID: 16449332
[Abstract] [Full Text] [Related]
19. The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response.
Luque-Ramírez M, Portoles GR, Varela C, Albero R, Halperin I, Moreiro J, Soto A, Casamitjana R, Spanish Multicentre Group for the Study of Acromegaly.
Horm Metab Res; 2010 Jan 12; 42(1):38-44. PubMed ID: 19798622
[Abstract] [Full Text] [Related]
20. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P, Hildebrandt G, Schaeffer HJ, Schönau E, Klug N.
Exp Clin Endocrinol Diabetes; 1998 Jan 12; 106(2):130-4. PubMed ID: 9628244
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
